BARDA contract worth up to $89M will support Basilea antibiotic

06/25/2013 | RTT News

The Biomedical Advanced Research and Development Authority granted Basilea Pharmaceutica a six-year contract worth as much as $89 million to support development of its novel monosulfactam antibiotic BAL30072. The drug, which is under development for severe infections, was chosen because of its broad coverage against multidrug-resistant Gram-negative pathogens. Basilea initially will get $17 million over 22 months.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC